Santaris to present miravirsen drug efficacy results
Miravirsen, which is developed using Locked Nucleic Acid (LNA) Drug Platform, is an inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication.
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.